APYX 8-K, filed Aug 10, 2020, 0000719135-20-000058

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
August 6, 2020
Date of Report (Date of earliest event reported)		APYX MEDICAL CORPORATION
---
(Exact name of registrant as specified in its charter)
Delaware	0-12183	11-2644611
---	---	---
(State or other jurisdiction of<br><br>incorporation or organization)	(Commission File Number)	(I.R.S. Employer<br><br>Identification No.)

5115 Ulmerton Road, Clearwater, FL 33760

(Address of principal executive offices, zip code)

(727) 384-2323

(Issuer’s telephone number)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	APYX	Nasdaq Stock Market, LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 5.07. Submission of Matters to a Vote of Security Holders.

On August 6, 2020, the following proposals were submitted to the stockholders of Apyx Medical Corporation (the "Company") at its annual meeting of stockholders: (i) the election of seven (7) directors; and (ii) the ratification of BDO USA, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2020.

The following are the final voting results for each proposal.

(i)	The Company’s stockholders elected each of the following seven (7) directors to serve on its Board of Directors until their successors are duly elected and qualified by the following vote:
	Name	Cast in Favor	Cast Against	Withheld
	Andrew Makrides	16,617,994	227,211	30,875
	Charles D. Goodwin	16,692,483	141,985	41,612
	Michael Geraghty	16,544,761	289,618	41,701
	Lawrence J. Waldman	16,538,314	295,515	42,251
	John Andres	16,542,248	291,631	42,201
	Craig Swandal	16,510,937	323,229	41,914
	Minnie Baylor-Henry	16,352,046	519,226	4,808	(ii)	The Company’s stockholders ratified the appointment of BDO USA, LLP as the Company's independent registered public accounting firm for the year ending December 31, 2020 by the following vote:
---	---	---	---
	Votes For	Votes Against	Votes Abstained
	22,568,286	308,689	46,291

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 10, 2020		APYX MEDICAL CORPORATION
	By:	/s/ Tara Semb
		Tara Semb
		Chief Financial Officer, Secretary, and Treasurer

Apyx Medical Corp 8-K, filed Aug 10, 2020

About this 8-K

Items reported